- Home
- GRBK vs CNTA Comparison
GRBK vs CNTA Comparison
Compare GRBK & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRBK
- CNTA
- Stock Information
- Founded
- GRBK 2006
- CNTA 2020
- Country
- GRBK United States
- CNTA United Kingdom
- Employees
- GRBK N/A
- CNTA N/A
- Industry
- GRBK Homebuilding
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- GRBK Consumer Discretionary
- CNTA Health Care
- Exchange
- GRBK Nasdaq
- CNTA Nasdaq
- Market Cap
- GRBK 2.6B
- CNTA 2.2B
- IPO Year
- GRBK N/A
- CNTA 2021
- Fundamental
- Price
- GRBK $57.69
- CNTA $11.58
- Analyst Decision
- GRBK Hold
- CNTA Strong Buy
- Analyst Count
- GRBK 3
- CNTA 9
- Target Price
- GRBK $65.50
- CNTA $25.63
- AVG Volume (30 Days)
- GRBK 280.8K
- CNTA 1.1M
- Earning Date
- GRBK 04-30-2025
- CNTA 03-24-2025
- Dividend Yield
- GRBK N/A
- CNTA N/A
- EPS Growth
- GRBK 37.62
- CNTA N/A
- EPS
- GRBK 8.45
- CNTA N/A
- Revenue
- GRBK $2,098,943,000.00
- CNTA N/A
- Revenue This Year
- GRBK $5.34
- CNTA N/A
- Revenue Next Year
- GRBK $7.55
- CNTA N/A
- P/E Ratio
- GRBK $6.61
- CNTA N/A
- Revenue Growth
- GRBK 18.07
- CNTA N/A
- 52 Week Low
- GRBK $51.76
- CNTA $7.75
- 52 Week High
- GRBK $84.66
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- GRBK 40.16
- CNTA 29.75
- Support Level
- GRBK $56.80
- CNTA $13.01
- Resistance Level
- GRBK $59.74
- CNTA $15.04
- Average True Range (ATR)
- GRBK 1.79
- CNTA 1.04
- MACD
- GRBK -0.25
- CNTA -0.36
- Stochastic Oscillator
- GRBK 37.14
- CNTA 0.39
About GRBK Green Brick Partners Inc.
Green Brick Partners Inc is a homebuilding and land development company. It acquires and develops land, as well as provides land and construction financing to its controlled builders. The company has three reportable segments: builder operations central, builder operations southeast, and land development. The majority of the company's revenue is generated from the builder operations central segment which is entirely the operations of builders in Texas. The company is engaged in various aspects of the homebuilding process, including land acquisition and development, entitlements, design, construction, marketing, sales, and brand image creation. In addition to homebuilding, the company provides home financing services, such as mortgage and title, through its subsidiaries.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.